949 / 1578
•
Phase I study; 16 Child-Pugh class A patients
•
Low Veff (<30%) n=4 and high Veff (30-60%) n=12);
•
Sorafenib escalation 100 mg > 400 mg > 800 mg daily
•
Results:
–
1/6 at 200 mg sorafenib daily: grade 3 ”tumor rupture”
–
6/12 with high Veff had worsening of Child-Pugh class
SBRT and sorafenib for HCC
Brade et al. IJROBP 2016;
94(3):580-7